Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data | Zendy

Michaël Hardy | Zendy; Isabelle Michaux | Zendy; Sarah Lessire | Zendy; Jonathan Douxfils | Zendy; JeanMichel Dogné | Zendy; Marion Bareille | Zendy; Geoffrey Horlait | Zendy; Pierre Bulpa | Zendy; Céline Chapelle | Zendy; Silvy Laporte | Zendy; Sophie Testa | Zendy; Hugues Jacqmin | Zendy; Thomas Lecompte | Zendy; Alain Dive | Zendy; François Mullier | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prothrombotic hemostasis disturbances in patients with severe COVID-19: Individual daily data

Author(s) -

Michaël Hardy,

Isabelle Michaux,

Sarah Lessire,

Jonathan Douxfils,

JeanMichel Dogné,

Marion Bareille,

Geoffrey Horlait,

Pierre Bulpa,

Céline Chapelle,

Silvy Laporte,

Sophie Testa,

Hugues Jacqmin,

Thomas Lecompte,

Alain Dive,

François Mullier

Publication year - 2020

Publication title -

data in brief

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.122

H-Index - 30

ISSN - 2352-3409

DOI - 10.1016/j.dib.2020.106519

Subject(s) - hemostasis , medicine , fibrinolysis , von willebrand factor , coagulation , fibrinogen , antithrombin , thrombosis , prospective cohort study , protein c , venous thrombosis , platelet , prothrombin time , protein s , pulmonary embolism , heparin

This data article accompanies the manuscript entitled: “Prothrombotic Disturbances of hemostasis of Patients with Severe COVID-19: a Prospective Longitudinal Observational Cohort Study” submitted to Thrombosis Research by the same authors. We report temporal changes of plasma levels of an extended set of laboratory parameters during the ICU stay of the 21 COVID-19 patients included in the monocentre cohort: CRP, platelet count, prothrombin time; Clauss fibrinogen and clotting factors II, V and VIII levels, D-dimers, antithrombin activity, protein C, free protein S, total and free tissue factor pathway inhibitor, PAI-1 levels, von Willebrand factor antigen and activity, ADAMTS-13 (plasma levels); and of two integrative tests of coagulation (thrombin generation with ST Genesia) and fibrinolysis (global fibrinolytic capacity - GFC). Regarding hemostasis, we used double-centrifuged frozen citrated plasma prospectively collected after daily performance of usual coagulation tests. Demographic and clinical characteristics of patients and thrombotic and hemorrhagic complications were also collected from patient's electronic medical reports.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research